Skip to content

    Cancer Health Center

    Font Size
    A
    A
    A

    Childhood Central Nervous System Embryonal Tumors Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview for CNS Embryonal Tumors

    Table 3. Standard Treatment Options for Childhood Central Nervous System (CNS) Embryonal Tumors

    Stage and/or Histopathologic Classification Standard Treatment Options
    Newly diagnosed childhood medulloblastoma:
    Children older than 3 years with average-risk medulloblastoma Surgery
    Adjuvant therapy(radiation therapy and chemotherapy)
    Children older than 3 years with high-risk medulloblastoma Surgery
    Adjuvant therapy(radiation therapy and chemotherapy)
    Children aged 3 years and younger Surgery
    Adjuvant chemotherapy
    Newly diagnosed CNS primitive neuroectodermal tumor:
    Children older than 3 years Surgery
    Adjuvant therapy(radiation therapy and chemotherapy)
    Children aged 3 years and younger Similar to children aged 3 years and younger with medulloblastoma (surgery and adjuvant chemotherapy)
    Newly diagnosed medulloepithelioma and ependymoblastoma Same as for children with high-risk medulloblastoma (surgery and adjuvant therapy) and children aged 3 years and younger with other embryonal tumors
    Newly diagnosed pineoblastoma:
    Children older than 3 years Surgery
    Adjuvant therapy(radiation therapy and chemotherapy)
    Children aged 3 years and younger Biopsy(for diagnosis)
    Chemotherapy
    High-dose, marrow-ablative chemotherapy with autologous bone marrow rescue or peripheral stem cell rescue
    Recurrent childhood CNS embryonal tumors (treatment options not considered standard) Surgery
    Radiation therapy
    Chemotherapy
    High-dose chemotherapy with stem cell rescue

    References:

    1. Zeltzer PM, Boyett JM, Finlay JL, et al.: Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17 (3): 832-45, 1999.
    2. Giangaspero F, Wellek S, Masuoka J, et al.: Stratification of medulloblastoma on the basis of histopathological grading. Acta Neuropathol 112 (1): 5-12, 2006.
    3. Eberhart CG, Kratz J, Wang Y, et al.: Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 63 (5): 441-9, 2004.
    4. Taylor MD, Northcott PA, Korshunov A, et al.: Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123 (4): 465-72, 2012.

    This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http:// cancer .gov or call 1-800-4-CANCER.

    WebMD Public Information from the National Cancer Institute

    Last Updated: 8/, 015
    This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
    1 | 2
    1 | 2
    Next Article:

    Today on WebMD

    man holding lung xray
    What you need to know.
    stem cells
    How they work for blood cancers.
     
    woman wearing pink ribbon
    Separate fact from fiction.
    Colorectal cancer cells
    Symptoms, screening tests, and more.
     
    Jennifer Goodman Linn self-portrait
    Blog
    what is your cancer risk
    HEALTH CHECK
     
    colorectal cancer treatment advances
    Video
    breast cancer overview slideshow
    SLIDESHOW
     
    prostate cancer overview
    SLIDESHOW
    lung cancer overview slideshow
    SLIDESHOW
     
    ovarian cancer overview slideshow
    SLIDESHOW
    Actor Michael Douglas
    Article